Image brain alpha synuclein deposition
- Trial ID
- NCT07348250
- Official Title
- An Open-label Study to Evaluate Brain α-Synuclein Deposition Using Positron Emission Tomography (PET) and [18F]MK-0947 in Patients With Parkinson's Disease
- Goal
- Image brain alpha synuclein deposition
- Phase
- EARLY_PHASE1
- Status
- RECRUITING
- Sponsor
- Invicro
- Study Type
- INTERVENTIONAL
- Enrollment
- 22 participants
- Conditions
- Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
- Interventions
- [18F]MK-0947
Plain-Language Summary
The goal is to find out whether a new PET tracer, [18F]MK-0947, can reliably show alpha-synuclein protein deposits in the brain of people with Parkinson's, which could help diagnose and track the disease. Participants receive a small injection of the radioactive tracer that binds to alpha-synuclein aggregates and is imaged with PET, often with MRI; the tracer is for imaging only, it does not treat Parkinson's and generally does not interfere with medications like levodopa. The study is enrolling adults 40 to 80 years old with Parkinson's and healthy older volunteers, plus a smaller group of healthy people aged 18 to 50, and requires informed consent, ability to tolerate PET/MRI and possible arterial sampling, no major medical issues, and not being pregnant.
Locations
- Invicro (dba Perceptive), New Haven, Connecticut, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying [18F]MK-0947. The goal is to find out whether a new PET tracer, [18F]MK-0947, can reliably show alpha-synuclein protein deposits in the brain of people with Parkinson's, which could help diagnose and track the disease. Participants receive a small injection of the radioactive tracer that binds to alpha-synuclein aggregates and is imaged with PET, often with MRI; the tracer is for imaging only, it does not treat Parkinson's and generally does not interfere with medications like levodopa. The study is enrolling adults 40 to 80 years old with Parkinson's and healthy older volunteers, plus a smaller group of healthy people aged 18 to 50, and requires informed consent, ability to tolerate PET/MRI and possible arterial sampling, no major medical issues, and not being pregnant.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 10 months.